The gadget analyzes images using artificial intelligence to achieve a degree of diagnosis accuracy that is not achievable with conventional manual grading techniques.
Hoffmann-La Roche
CENTERSTONE is the first worldwide phase III trial that shows how effective an antiviral medication is at slowing the spread of a respiratory virus.
More than 12,000 new jobs will be created by investments, including 1,000 at Roche and more than 11,000 to support the development of new manufacturing capabilities in the US.
Columvi therapy provides a much-needed, off-the-shelf, fixed-duration alternative for transplant ineligible individuals.
In a randomized phase III study, Gazyva®/Gazyvaro® is the only anti-CD20 monoclonal antibody that shows a full renal response benefit.
